688198.SS
688198.SS
CNE100005X15
BEIJING BALANCE MEDICAL TECHNOL
Loading chart...

Company Profile

Beijing Balance Medical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of artificial bioprosthetic valve medical devices in China and internationally. It offers bovine pericardial, porcine aortic tissue, and limiting expandable artificial biological heart valves, as well as tricuspid annuloplasty ring for heart valve repair and treatment. The company also provides outflow tract single valve patch, pulmonary valved conduit, cardiothoracic biopatch, thoracic surgery biological patch, and dacron patch, as well as ventricular septal defect occluder, PDA occluder, ASD occluder, and cardiovascular occluder delivery system for congenital heart disease treatment. In addition, it offers neurosurgery microvascular pressure relief gasket, neurosurgical biopatch, and biological hernia patch for soft tissue repair. The company was founded in 2001 and is headquartered in Beijing, China.

Related stocks

2675.HK
2675.HK • China
EDGE MEDICAL-B
33 HKD
1.64B USD
688016.SS
688016.SS • China
SHANGHAI MICROPORT ENDOVASCULAR
84.9 CNY
1.57B USD 1Y -24.7%
2697.HK
2697.HK • China
TH MEDICAL-B
183 HKD
1.2B USD
300298.SZ
300298.SZ • China
CHANGSHA SINOCARE
16.68 CNY
1.39B USD 1Y -16.4%
600587.SS
600587.SS • China
SHINVA MEDICAL INSTRUMENT CO LT
13.12 CNY
1.19B USD 1Y -19.8%
600055.SS
600055.SS • China
BEIJING WANDONG MEDICAL TECHNOL
10.48 CNY
1.1B USD 1Y -41.3%
0853.HK
0853.HK • China
MICROPORT
6.08 HKD
1.48B USD 1Y -59%
300143.SZ
300143.SZ • China
INKON LIFE
7.95 CNY
1.16B USD 1Y -9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
41.9% p.a.
Max Drawdown (5Y)
-65.7%
Sharpe Ratio (5Y)
-0.44
Beta Factor
0.02
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 55.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (41.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -65.7% in the extended horizon.
ende